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Cancer patients often suffer from cancer
cachexia and paraneoplastic syndrome,
which significantly impair survival and
the quality of life. Here, Lim et al. report
that tumor-derived VEGF induces anemia
in mice through the mechanism of vessel
dilation in bone marrow. The VEGF-
VEGFR2-triggered vascular dilation in
bone marrow leads to mobilization of
bone marrow cells to peripheral tissues
and organs. These findings suggest a
therapeutic option for treatment of cancer
anemia by targeting VEGF-VEGFR2
signaling.
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Molecular mechanisms underlying tumor VEGF-
induced host anemia and bone marrow cell (BMC)
mobilization remain unknown. Here, we report that
tumor VEGF markedly induced sinusoidal vascula-
ture dilation in bonemarrow (BM) and BMCmobiliza-
tion to tumors and peripheral tissues in mouse and
human tumor models. Unexpectedly, anti-VEGFR2,
but not anti-VEGFR1, treatment completely blocked
VEGF-induced anemia and BMC mobilization.
Genetic deletion of Vegfr2 in endothelial cells mark-
edly ablated VEGF-stimulated BMC mobilization.
Conversely, deletion of the tyrosine kinase domain
from Vegfr1 gene (Vegfr1TK/) did not affect VEGF-
induced BMC mobilization. Analysis of VEGFR1+/
VEGFR2+ populations in peripheral blood and BM
showed no significant ratio difference between
VEGF- and control tumor-bearing animals. These
findings demonstrate that vascular dilation through
the VEGFR2 signaling is the mechanism underlying
VEGF-induced BM mobilization and anemia. Thus,
our data provide mechanistic insights on VEGF-
induced BMCmobilization in tumors and have thera-
peutic implications by targeting VEGFR2 for cancer
therapy.INTRODUCTION
In the tumor microenvironment, tumor cells together with other
host cellular components including inflammatory cells, stromal
fibroblasts, and vascular cells collectively contribute to tumorCdevelopment, progression, invasion, and metastasis (Hanahan
and Weinberg, 2011). Malignant cells and the tumor-infiltrated
host cells reciprocally interact with each other. This complex
and intimate crosstalk is accomplished through various growth
factors, cytokines, and cell-cell interactions. Genetic and epige-
netic alterations, as well as microenvironmental changes, often
lead to production of various growth factors and cytokines at
high levels. Vascular endothelial growth factor (VEGF) is one of
the most frequently highly expressed angiogenic factors found
in various tumor tissues (Jubb et al., 2004), and its expression
level can be further elevated by tissue hypoxia that often exists
in solid tumor (Makino et al., 2001). Although VEGF is described
as one of the relatively specific endothelial growth factors, it dis-
plays broad biological functions by targeting other cell types,
including tumor, perivascular, hematopoietic, inflammatory,
and neuronal cells (Cao, 2014; Ferrara et al., 2003). These broad
tissue effects are determined by the specific distribution of
VEGFRs on particular cell types.
VEGF displays its biological functions by activation of its re-
ceptors, and it is generally believed that VEGFR2, a cell-surface
tyrosine kinase receptor, is the functional receptor that
mediates VEGF-induced angiogenesis, vascular permeability,
and vascular remodeling (Ferrara et al., 2003; Senger et al.,
1983). Conversely, biological functions of VEGFR1-mediated
signals remain largely unknown, and it has been suggested
that VEGFR1 mediates negative signals that counteract VEGF-
induced angiogenesis (Cao, 2009). Based on its relatively broad
distribution in various cell types, some of the VEGF-induced non-
endothelial activity has been associated with the VEGFR1-
signaling system. For example, VEGFR1 is expressed in
macrophages and hematopoietic progenitor cells and has
been reported to be involved in recruiting these cells to the
tumor microenvironment (Cao, 2009). Once these hemato-
poietic progenitor and inflammatory cells are recruited to the
tumor microenvironment, they significantly contribute to tumorell Reports 9, 569–580, October 23, 2014 ª2014 The Authors 569
neovascularization. Additionally, VEGF-mobilized bone marrow
cells (BMCs) may significantly contribute to cancer metastasis
by facilitating malignant cell intravasation and the formation of
premetastatic niches in remote organs (Kaplan et al., 2005;
Wynn et al., 2013).
In this study, we use several mouse tumor models to study the
underlying mechanism by which tumor-derived VEGFs mobilize
BMCs. Surprisingly, we found that the mechanism underlying
the VEGF-induced BMC mobilization is mediated via VEGFR2-
dependent vascular dilation in bone marrow (BM) but indepen-
dent from VEGFRs expression in BMCs. Thus, targeting
endothelial cell VEGFR2, but not VEGFRs in hematopoietic cells,
would be an effective approach to inhibit VEGF-stimulated
BMCs, which may significantly participate in tumor growth,
angiogenesis, and metastasis.
RESULTS
Tumor-Derived VEGF Induces BMC Mobilization,
Vascular Dilation, and Permeability
To study the systemic impact of tumor-derived VEGF on BMCs,
we established a murine fibrosarcoma (T241) cell line that pro-
duces VEGF165 (Xue et al., 2008; Yang et al., 2013a; Zhang
et al., 2011). Tumor cells were subcutaneously implanted in syn-
geneic wild-type (WT) C57Bl6 mice, and BMwas analyzed when
tumor volume reached approximately 1 cm3 in vector- and
VEGF-T241 tumors. The tumor-derived circulating VEGF was
detectable in plasma of tumor-bearing mice. The plasma level
of VEGF-tumor-bearing mice was significantly higher than that
of control tumor-bearing mice (1.2 ng/ml versus 0.06 ng/ml;
Figure S1A). Compared with vector-tumor control mice, VEGF-
tumor-bearing mice exhibited a severe hematopoietic defect,
manifesting robust depletion of BMCs, with an exception of re-
maining BMCs attached to the bone matrix (Figure 1A). Quanti-
fication analysis showed a significant reduction of BMCs in
VEGF-tumor-bearing mice relative to controls (Figure 1C).
Vascular immunohistochemical staining with endomucin as a
sinusoidal endothelial-cell-specific marker (Wang et al., 2013)
demonstrated that BM microvessels underwent marked dilation
in VEGF-tumor-bearing animals relative to control groups (Fig-
ure 1B). Owing to dilation of sinusoidal microvessels in BM,
vascular density per fieldwas significantly decreased (Figure 1C).
Notably, BM microvessels were also dilated in vector control tu-
mor-bearing mice, although this effect remains relatively modest
(Figures 1A–1C). Consistent with BM defects, peripheral red
blood cells (RBCs), hemoglobin (HGB), and hematocrit (HCT) in
VEGF-tumor-bearing mice were all significantly decreased rela-
tive to those of tumor-free healthy mice (Figure S1B).
Similar to VEGF165, overexpression of VEGF121, a non-hepa-
rin-binding soluble VEGF isoform, in tumors also markedly
induced BM vessel dilation and BMC loss (Figure S2). In
contrast, expression of VEGF189, a high-affinity heparin-binding
VEGF isoform, did not alter BM vasculatures and BMCmobiliza-
tion (Figure S2). These findings indicate that non-heparin-
binding soluble VEGF molecules are responsible for BM vessel
dilation and BMC loss. In contrast to VEGF, overexpression of
PlGF and VEGF-B in the same tumor type did not induce vessel
dilation and BMC loss (Figure S2). Because PlGF and VEGF-B570 Cell Reports 9, 569–580, October 23, 2014 ª2014 The Authorsare VEGFR1 exclusive binding ligands, which lack interactions
with VEGFR2, these findings provide independent evidence to
further support the VEGFR2-dependent mechanism underlying
VEGF-induced BMC loss.
To exclude the possibility that BMC loss was the causal mech-
anism of BM vessel dilation, we employed irradiation as an alter-
native approach to induce BMC loss. As expected, irradiation
effectively induced BMC loss in mice without causing vessel
dilation (Figures 1D and 1E). These findings suggest that BMC
loss per se would not significantly alter BM vessel dilation, and
VEGF-induced vessel dilation and BMC loss occurred as a
sequential event. The other possible mechanism underlying
VEGF-induced BMC mobilization is the increase of vascular
permeability of BM vasculatures. To study this possibility,
large-size rhodamine-labeled 2,000 kDa dextran molecules
were injected into tumor-bearing mice. Notably, BM vascula-
tures of VEGF-tumor-bearing mice showed high permeability
of 2,000 kDa dextran whereas BM vasculatures of vector control
tumor-bearing mice were completely nonpermeable to these
large-size dextran molecules (Figures 1F and 1G). In fact, nearly
all injected dextranmolecules were extravasated in BMof VEGF-
tumor-bearing mice. The highly permeable BM vessels are likely
to provide another mechanism of BMC mobilization. Consistent
with increased mobilization of BMCs, peripheral blood mono-
nuclear cells (PBMCs) were transiently increased, followed by
a decrease (Figure 1H). The fluctuation of white blood cells
(WBCs) reflects the dilation-permeability-related mobilization of
BMCs and subsequently BM crisis.
VHL Mutation-Induced VEGF in Human Renal Cell
Carcinomas Causes BM Vascular Dilation and Anemia
To link our findings to pathophysiological relevance, we studied
the impact of tumor-derived VEGF on BM vessels in natural-
occurring human tumors. For this reason, we chose a human
renal cell carcinoma (768-O RCC-mutVHL) with VHL mutations,
which often leads to high expression of VEGF due to stabilization
of hypoxia-inducible factor-1a (HIF-1a). Reconstitution of
WTVHL into the 768-O RCC-mutVHL enabled us to use the cell
line of the same background to study the role of VHL mutation
in modulation of BM vascular dilation and BMC mobilization.
The circulating VEGF level of 768-O RCC-mutVHL-tumor-
bearing mice was high (approximately 500 pg/ml) as compared
with that of 768-O RCC-WTVHL-tumor-bearing mice (Figure 2A).
Consistent with the high-circulating VEGF level, 768-O RCC-
mutVHL-tumor-bearing mice exhibited suppression of BM
hematopoiesis by losing BMCs (Figure 2B). Examination of BM
microvessels demonstrated that BM vasculatures became
highly dilated, as seen in the mouse tumor models (Figure 2C).
The sinusoidal BM microvessels appeared to be disorganized
with large and irregular lumen as compared with those of
768-O RCC-WTVHL-tumor-bearing mice (Figure 2D). Consistent
with BM morphology, 768-O RCC-mutVHL-tumor-bearing mice
suffered from anemia with reduced RBCs, HGB, and HCT values
(Figure 2E). These findings in human renal cell carcinoma (RCC)
tumors demonstrate the pathophysiological relevance of our
findings and indicate that VHL mutations potentially contribute
to development of tumor-associated anemia through the mech-
anism of VEGF-induced BM vessel dilation.
Figure 1. Tumor-Derived VEGF Induces BMC Mobilization and Sinusoidal Vascular Dilation
(A) Hematoxylin and eosin (H&E) staining of BM obtained from the joint region between femur and tibia of tumor-free, vector-, and VEGF-tumor-bearing mice
(n = 4‒6). Arrows point to BMCs.
(B) Upper panels: endomucin staining of microvessels in BM of tumor-free, vector-, and VEGF-tumor-bearing mice. Lower panels: pseudosimulation of
microvessels shown in upper panels. The dash-line-encircled areas show lumens of microvessels. Last panels: endomucin (red) and DAPI (blue) double
immunostaining shows the relation between BM microvessels and BMCs. Arrows indicate microvessels.
(C) Quantification of numbers of BMCs, microvessels, and sinusoidal areas of microvessels (n = 6‒8).
(D) Irradiated WT C57Bl6 mouse BM was double immunostained with endomucin (red) and DAPI (blue; n = 6). White arrows indicate BMCs, and yellow arrows
indicate intercellular distances of irradiated BM. Arrowheads point to microvessels in BM.
(E) Quantification of numbers of BMCs, BM microvessels, and BM vascular sinusoidal areas (n = 6‒8).
(F) Perfusion of lysinated 2,000 kDa dextran (green) in BMmicrovessels that were costainedwith endomucin (red) of vector- and VEGF-tumor-bearingmice (n = 6).
Arrows indicate perfused area (yellow). Arrowheads point to extravasated dextran signals (green).
(G) Quantification of vascular perfusion and extravasated dextran signals (n = 6‒8). LRD, lysinated rhodamine dextran.
(H) WBCs from peripheral blood of tumor-free and VEGF tumor-bearing mice were measured (n = 4‒6).
The scale bars of each panel represent 50 mm. All data are represented as mean ± SEM. **p < 0.01; ***p < 0.001 (Student’s t test; two-tailed). See also Figure S1.VEGFR2-Dependent Vessel Dilation and BMC
Mobilization
We next studied the VEGFR-signaling pathway that mediates
microvessel dilation and BMC mobilization. Anti-mouse
VEGFR1- and VEGFR2-specific neutralizing antibodies (Yang
et al., 2013b) were used to block VEGF-triggered functions.
Interestingly, VEGFR2-, but not VEGFR1-, specific blockadeCvirtually completely reversed the VEGF-induced BM defect (Fig-
ure 3A). The density of BMCs in VEGFR2 blockade-treated tu-
mor-bearing mice reversed to similar levels of healthy and vector
tumor controls (Figure 3C). Consistent with BMC recovery, anti-
VEGFR2-treated VEGF-tumor-bearing mice showed normali-
zation of BM vessels with substantial reduction of vascular
diameters nearly to those seen in control-vector-tumor-bearingell Reports 9, 569–580, October 23, 2014 ª2014 The Authors 571
Figure 2. Natural Human-Tumor-Derived VEGF Induces BM Vessel
Dilation and Anemia
(A) Circulating levels of VEGF in 768-O RCC-mutVHL- and 768-O RCC-
WTVHL-tumor-bearing mice (n = 5).
(B) H&E staining of BM obtained from femur and tibia of 768-O RCC-mutVHL-
and 768-O RCC-WTVHL-tumor-bearing mice (n = 5). Arrows point to BMCs.
(C) Endomucin staining (red) of microvessels in BM of various groups. Arrows
indicate microvascular structures. Endomucin and DAPI (blue) double immu-
nostaining shows the relation between BM microvessels and BMCs. Arrows
indicate microvascular structures.
(D) Quantification of numbers of BMCs, numbers of microvessels, and sinu-
soidal areas of microvessels (n = 6‒8).
(E) RBCs, HGB, and HCT from peripheral blood of 768-O RCC-mutVHL- and
768-O RCC-WTVHL-tumor-bearing mice were measured (n = 5).
The scale bars of each panel represent 50 mm. All data are represented as
mean ± SEM. **p < 0.01, ***p < 0.001 (Student’s t test; two-tailed).mice (Figures 3B and 3E). Consequently, microvessel density
was significantly increased as measured per field of BM sec-
tions (Figure 3D). Similar to VEGFR2 blockade, treatment of
VEGF-tumor-bearing mice with an anti-mouse VEGF neutral-
izing antibody resulted in recovery of BMCs and vascular
normalization (Figures 3A–3E). In sharp contrast, treatment
with the VEGFR1 blockade did not significantly affect tumor
VEGF-induced vessel dilation and BMC mobilization (Figures
3A–3E). To provide further supportive evidence of VEGFR2572 Cell Reports 9, 569–580, October 23, 2014 ª2014 The Authorsactivation in endothelial cells, we isolated endothelial cells
from BM of VEGF- and vector-tumor-bearing mice. Notably,
a substantial amount of VEGFR2 molecules became phos-
phorylated in BM endothelial cells of VEGF-tumor-bearing
mice as compared with those in vector-tumor-bearing mice
(Figure 3F). These findings indicate that VEGFR2-mediated
signaling is crucial for tumor VEGF-stimulated BMC
mobilization.
VEGFR2 Blockade Inhibits BMC Mobilization to Tumor
and Peripheral Tissues
To trace mobilization of BMCs to tumor and peripheral tissues,
we next performed bone marrow transplantation experiments
using BMCs from enhanced GFP (EGFP) mice. In these experi-
mental settings, C57Bl6 syngeneic recipient mice were irradi-
ated, followed by BM transplantation with EGFP+ BMCs from
the donor. Xenograft of T241 tumor cells were subcutaneously
implanted into recipient mice after 3 weeks of BM transplanta-
tion, and tumor-bearing mice were randomly divided into
different groups that received various treatments. Consistent
with VEGF-induced BMC depletion, tumor-derived circulating
VEGF molecules were able to markedly increase mobilization
of EGFP+ BMCs to tumor and hepatic tissues relative to that
of vector-control tumor-bearing mice (Figures 4A–4C). The
increased EGFP+ BMCs to tumor and hepatic tissues were
unlikely due to the consequence of increased proliferation of
the resident BMCs because these cells were not actively prolif-
erating (Figures 4D and 4E). These findings further validate the
fact that circulating VEGF significantly mobilized BMCs to
peripheral tissues, resulting in a decreased number of resident
cells in BM.
Interestingly, treatment of tumor-bearing recipient mice with
the VEGFR2 blockademarkedly prevented VEGF-inducedmobi-
lization of BMCs to tumors and liver (Figures 4A–4C), supporting
the critical role of VEGFR2 in mediating mobilization of BMCs to
peripheral tissues. Likewise, a VEGF-specific blockade pro-
duced a similar inhibitory effect on BMC mobilization in tumor
and liver (Figures 4A–4C). Again, VEGFR1 blockade had no
effect on mobilization of EGFP+ BMCs to tumor and liver. These
findings further support the fact that VEGFR2-, but not VEGFR1-,
mediated signals are essential for BMCmobilization in our tumor
models.
Reversible Recovery of Hematopoiesis and
Microvasculature after Tumor Removal
Because VEGFR1 and VEGFR2 are expressed in subsets of
hematopoietic cells and WBCs (Kumar et al., 2003; Lyden
et al., 2001), it is possible that pharmacological interference
with VEGFR1 and VEGFR2 blockades would affect BMC pro-
duction under physiological conditions. It is also highly
possible that VEGF plays a crucial role in maintenance of
BM microvasculatures. Thus, the effects of anti-VEGFR1 and
anti-VEGFR2 treatments in our tumor models could be due
to their direct impact on BMCs and microvasculatures,
which were not influenced by tumors. To exclude these possi-
bilities, we treated tumor-free healthy mice with VEGFR1
and VEGFR2 blockades. Notably, neither VEGFR1 nor VEGFR2
blockades produced any significant effects on the total
Figure 3. VEGFR2 Blockade Inhibits Circulating VEGF-Induced BM Vascular Dilation and BMC Depletion
(A) H&E staining of vehicle-, anti-VEGFR1-, and anti-VEGFR2-treated and nontreated BM from VEGF-tumor-bearing mice (n = 6). BMs from tumor-free and
vector-tumor-bearing mice served as controls. Arrows point to BMCs.
(B) Endomucin (red) and DAPI (blue) double immunostaining shows the relation between BMmicrovessels and BMCs. Arrows indicate microvascular structures.
(C‒E) Quantification of numbers of BMCs (C), numbers of microvessels (D), and sinusoidal areas of microvessels (E). n = 6‒8; ns, not significant.
(F) Detection of phosphorylated VEGFR2 by western blot in endothelial cells of BM isolated from vector- and VEGF-tumor-bearing mice. Actin was used for
standard loading.
The scale bars of each panel represent 50 mm. All data are represented as mean ± SEM. ***p < 0.001 (Student’s t test; two-tailed). See also Figure S2.BMC population, microvessel density, and vascular dilations
(Figure S3A).
To study if tumor-derived VEGF-induced BMC depletion and
vascular dilation were reversible, we next performed experi-
ments by removing primary tumors in mice that had already
developed severe BM phenotypes. Expectedly, BMCs and BM
microvessels were almost completely recovered after only
2-week tumor removal (Figure S3B). These findings further
demonstrate that tumor-derived VEGF is primarily responsible
for causing the BM phenotype. To further study if tumor-
removal-recovered BMCs and microvasculatures were depen-
dent on VEGF, three groups of mice, upon resection of primaryCtumors, were treated with VEGFR1, VEGFR2, and VEGF block-
ades, respectively. Interestingly, all three anti-VEGF agents
had no effects on BMC and microvasculature recovery after
removing primary tumors (Figure S3C).
Genetic Inactivation of VEGFR1 Does Not Affect
VEGF-Induced BMC Mobilization
In addition to pharmacological interference, we next studied
the role of VEGF-induced BMC mobilization and vascular
dilation in Vegfr1TK/ mice that only carry the tyrosine-ki-
nase-deleted Vegfr1 gene (Hiratsuka et al., 1998; Yang
et al., 2013a). Stimulation of WT cells including endothelialell Reports 9, 569–580, October 23, 2014 ª2014 The Authors 573
Figure 4. Effects of VEGF, VEGFR1, and VEGFR2 Blockades on
Mobilization of Transplanted EGFP+ BMCs
(A) Infiltration of EGFP+ BMCs in tumors and livers of BM-transplanted VEGF-
tumor-bearing mice that received treatment of VEGF-, VEGFR1-, and
VEGFR2-specific blockades (n = 6‒8). Vector tumor bearing was used as
control (n = 6‒8). Arrows indicate EGFP+ BMCs.
(B and C) Quantification of numbers of EGFP+ BMCs in tumors (B) and in livers
(C) of each group (n = 6‒8). ns, not significant.
(D) Ki67 (red) and DAPI (blue) double immunostaining of infiltrated
EGFP+ BMCs in tumors and livers of BM-transplanted vector- and VEGF-
tumor-bearing mice (n = 6‒8). Arrows indicate Ki67+-EGFP+ BMCs. ns, not
significant.
(E) Quantification of the percentage of Ki67+-proliferative EGFP BMCs
(n = 6‒8).
The scale bars of each panel represent 50 mm. All data are represented as
mean ± SEM. *p < 0.05; ***p < 0.001 (Student’s t test; two-tailed). See also
Figure S3.
Figure 5. Tumor VEGF-Induced Mobilization of BMCs and Sinusoi-
dal Vascular Dilation in Vegfr1TK/ Mice
(A) Western blot detection of phosphorylation of VEGFR1 by VEGF in cells
isolated from BM of WT and Vegfr1TK/ mice. Actin was used for standard
loading. IB, immunoblot; IP, immunoprecipitation.
(B) H&E staining of BM of tumor-free, vector-tumor-bearing, and VEGF-tumor-
bearing Vegfr1TK/ mice (n = 6). Arrows point to BMCs.
(C) Endomucin staining of microvessels in BM of tumor-free, vector-tumor-
bearing, and VEGF-tumor-bearing Vegfr1TK/ mice. Arrows indicate micro-
vascular structures. Endomucin (red) and DAPI (blue) double immunostaining
shows the relation between BM microvessels and BMCs. Arrows indicate
microvascular structures.
(D‒F) Quantification of numbers of BMCs (D), numbers ofmicrovessels (E), and
sinusoidal areas of microvessels (F). n = 6‒8.
The scale bars of each panel represent 50 mm. All data are represented as
mean ± SEM. ***p < 0.001 (Student’s t test; two-tailed). See also Figure S4.cells isolated from BM resulted in phosphorylation of VEGFR1
(Figure 5A). However, VEGFR1 activation was abolished in
VEGF-stimulated Vegfr1TK/ BM (Figure 5A). These results
validate the defective VEGFR1 signaling in Vegfr1TK/
mice. Intriguingly, tumor VEGF-induced BMC mobilization
and BM vascular dilation were not affected in Vegfr1TK/
mice as compared with their littermates (Figures 5B–5F). In
fact, the VEGF-induced BM phenotypes were virtually indis-
tinguishable in Vegfr1TK/ mice as compared with those of574 Cell Reports 9, 569–580, October 23, 2014 ª2014 The AuthorsWT mice (Figures 1A–1C). Similarly, values in peripheral blood
including RBCs, HCT, HGB, and WBCs in tumor-bearing and
non-tumor-bearing Vegfr1TK/ mice were virtually identical to
those seen in WT mice (Figure S1C). These findings further
Figure 6. Tumor VEGF-Induced Mobiliza-
tion of BMCs and Sinusoidal Vascular Dila-
tion in Vegfr2lox/loxTie2CreERT Mice
(A) VEGFR2 and endomucin double immuno-
staining of BM. Arrowheads point to VEGFR2 and
endomucin double-positive signals.
(B) VEGFR2 and Tie2 double immunostaining of
BM. Arrowhead points to VEGFR2 and Tie2
double-positive BMmicrovessels. Arrows indicate
Tie2 positive nonendothelial-cell signals.
(C) Quantification of Vegfr2 mRNA expression in
BM of tamoxifen-treated and nontreated tumor-
free Vegfr2lox/loxTie2CreERT mice (n = 6).
(D) H&E staining of BM of tamoxifen-treated and
nontreated vector-tumor-bearing and VEGF-
tumor-bearing Vegfr2lox/loxTie2CreERTmice. Arrows
point to BMCs.
(E) Endomucin staining of microvessels in BM of
tamoxifen-treated and nontreated vector-tumor-
bearing and VEGF-tumor-bearing Vegfr2lox/lox
Tie2CreERT mice. Arrows indicate microvascular
structures. Endomucin (red) and DAPI (blue) dou-
ble immunostaining shows the relation between
BM microvessels and BMCs. Arrows indicate
microvascular structures.
(F) Quantification of numbers of BMCs, numbers
of microvessels, and sinusoidal areas of micro-
vessels (n = 6‒8).
The scale bars of each panel represent 50 mm. All
data are represented as mean ± SEM. **p < 0.01;
***p < 0.001 (Student’s t test; two-tailed). See also
Figure S5.strengthen our conclusion that VEGFR2, but not VEGFR1,
mediates VEGF-induced BMC depletion and BM vascular
changes.Cell Reports 9, 569–580,Endothelial Deletion of Vegfr2
Abrogates VEGF-Induced BMC
Mobilization
Knowing that VEGFR2 was the crucial
receptor for VEGF-induced BMC mobili-
zation, we investigated the in-depth
mechanism that underlies VEGF-induced
BMC mobilization. A tamoxifen-inducible
Tie2CreERTmouse strain was crossed with
Vegfr2lox/lox (Sato et al., 2011) to generate
conditional Vegfr2lox/loxTie2CreERT-defi-
cient mice in endothelial cells. We first
performed localization studies to detect
VEGFR2 and Tie2 expression in BM.
Notably, VEGFR2 expression was
restricted to endothelial cells as cos-
tained with the endothelial cell marker en-
domucin (Figure 6A). However, the Tie2+
signals were less specific for BM vascula-
tures, and nonendothelial-cell-positive
signals were also detected (Fig-
ure 6B). These Tie2+ nonendothelial cells
might represent Tie2+monocytes/macro-
phages as described elsewhere (DePalma et al., 2005). Because VEGFR2 expression was restricted
in vascular endothelial cells, crossing Vegfr2lox/loxwith Tie2CreERT
would only allow excising Vegfr2 in endothelial cells. ConditionalOctober 23, 2014 ª2014 The Authors 575
Figure 7. Diagram of Endocrine Functions of Tumor-Derived VEGF
Tumor-derived soluble VEGF enters the circulation and causes sinusoidal
dilation of bone marrow microvessels. Vascular dilation of sinusoidal capil-
laries results in reduced hematopoietic areas and drives out BMCs, leading to
an anemic phenotype. VEGF-induced mobilization of BMCs significantly
contributes to tumor invasion and metastasis.Vegfr2lox/loxTie2CreERT-deficient mice showed significant reduc-
tion of Vegfr2mRNA expression (Figure 6C). It should be empha-
sized that Vegfr2lox/loxTie2CreERT-deficient mice only showed
approximately 30% reduction of VEGFR2 expression. Implanta-
tion of VEGF tumors in Vegfr2lox/loxTie2CreERT-deficient mice
significantly abrogated VEGF-induced vascular dilation in BM
(Figures 6D–6F). Importantly, BMCs were markedly recovered
in VEGF tumor bearing in Vegfr2lox/loxTie2CreERT-deficient mice,
resulting in a normalized hematopoietic phenotype (Figures
6D–6F). In addition, microvessel density was also markedly
increased in VEGF tumor bearing in Vegfr2lox/loxTie2CreERT-defi-
cient mice (Figure 6F). These findings provide compelling evi-
dence that VEGF-induced BM microvessel dilation through the
VEGFR2 signaling in endothelial cells is responsible for VEGF-
induced BMC mobilization.
Mobilization of VEGFR1- and VEGFR2-
Independent BMCs
To study if circulating VEGF preferentially mobilized subpopula-
tions of VEGFR1+ or VEGFR2+ cells, we performed fluores-
cence-activated cell sorting (FACS) analysis in BM and
peripheral blood. To ensure that specific anti-VEGFR1 and
anti-VEGFR2 antibodies against mouse were working in our
experimental settings, CD31+ endothelial cell fractions from
tumor tissues were used as positive controls. As expected,
CD31+ endothelial cell fractions showed positive signals in
both anti-VEGFR1 and anti-VEGFR2 analyses (Figure S4A). In
contrast, a human ovarian cell line completely lacked detectable
signals in our FACS analysis (Figure S4A). These findings
demonstrate that our anti-VEGFR1- and anti-VEGFR2-based
FACS analyses are workable in our experimental settings. Under
physiological conditions, VEGFR1+ and VEGFR2+ cells consti-576 Cell Reports 9, 569–580, October 23, 2014 ª2014 The Authorstuted only minor populations of total peripheral blood cells
(0.06% VEGFR1+ cells and 0.43% VEGFR2+ cells; Figures
S4B–S4D). In vector-tumor-bearing mice, VEGFR1+ and
VEGFR2+ cell populations in the peripheral were not significantly
altered (0.23% VEGFR1+ cells and 0.22% VEGFR2+ cells; Fig-
ures S4B–S4D). Moreover, implantation of VEGF tumors in
mice did not dramatically increase the VEGFR1+ and VEGFR2+
cell populations in peripheral blood (0.19% VEGFR1+ cells and
0.47%VEGFR2+ cells; Figure S4B–S4D). These findings demon-
strate that tumor-produced circulating VEGF did not alter the
percentages of VEGFR1+ and VEGFR2+ cell populations in
peripheral blood, implying that active mobilization of these
VEGFR+ cells would unlikely be the mechanism underlying the
robust effect of VEGF-induced mobilization. It should be empha-
sized that VEGFR1+ plus VEGFR2+ under all conditions only
constituted only <1% of the total nuclear+ cell population in
peripheral blood. Thus, this tiny population cannot account for
substantial mobilized cells by circulating VEGF.
Consistent with peripheral ratios of VEGFR1+ and VEGFR2+
cell populations, VEGFR1+ and VEGFR2+ BMC populations
were not altered in BM of vector- and VEGF-tumor-bearing
mice (Figures S4E–S4G). Again, the total VEGFR1+ and
VEGFR2+ BMCs represent only a tiny population (<0.4%) of total
BMCs. There were no significant ratio changes in tumor-free,
healthy, vector-tumor and VEGF-tumor mice. Similarly, the pop-
ulations of putative Lin()/c-Kit(+)/Sca-1(+) hematopoietic stem
cells and CD45+ myeloid cells in BM remained unchanged in
tumor-free, healthy, vector-tumor and VEGF-tumor mice (Fig-
ure S5). These findings suggest that preferential mobilization of
VEGFR+ BMCs is unlikely a mechanism of VEGF-induced BMC
depletion and peripheral mobilization.
DISCUSSION
We have recently discovered that tumor-derived circulating
VEGF represses bone marrow hematopoiesis by mobilizing
BMCs (Figure 7; Xue et al., 2008; Zhang et al., 2011). Consis-
tently, others have also reported that VEGF mobilizes BMCs
under various pathological conditions through a possible mech-
anism of interacting with VEGFRs expressed in BMCs (Shaked
et al., 2006). Unlike the restricted expression of VEGFR2 in a
limited number of cells, VEGFR1 exhibits relatively broad
expression patterns on a variety of cell types including mono-
cytes/macrophages and granulocytes (Cao, 2009). Based on
expression of VEGFR1 on certain types of BMCs and infiltration
of these cells in tumor tissues, it has been suggested that VEGF
is able to mobilize these cells from BM to tumor tissues. Despite
this reasonable hypothesis, experimental evidence has been
lacking to support selective mobilization of VEGFR1+ BMCs by
tumor-derived VEGF. In addition to VEGF, several other factors
including angiopoietin1, stroma-derived factor, and granulo-
cyte-colony-stimulating factor have been reported to induce
BMC mobilization (Ryan et al., 2010; Youn et al., 2011).
Our present study provides several lines of evidence to
exclude a direct role of VEGF in mobilization of specific VEGFR+
BMC populations. These include (1) stochastic depletion of
BMCs by circulating VEGF that resulted in only scattered
hematopoietic islets being attached to the bone matrix;
(2) VEGF-induced BMCs depletion occurred in large areas of
BM but unlikely vaporized only a particular cell population; (3)
despite its broad distribution in BMCs, pharmacological and ge-
netic inactivation of VEGFR1 produced no impact on BMC
mobilization; (4) cell population analysis demonstrated that the
ratio of VEGF-mobilized VEGFR+ and VEGFR cells in periph-
eral blood and tissues remained the same as controls, indi-
cating that mobilization occurred indistinctly on all BMCs;
(5) inactivation of VEGFR2, which is expressed in a tiny popula-
tion of BMCs, could virtually completely block tumor VEGF-
induced BMC mobilization; and (6) overexpression of VEGFR1
exclusive binding ligands including PlGF and VEGF-B in tumors
did not induce vessel dilation and BMC loss. The compelling ev-
idence provided from these data suggests the existence of
alternative mechanisms. Examination of blood vessels, the
main VEGFR2+ structural component in BM, showed that BM si-
nusoidal microvessels became high dilated, and the majority of
BM area was replaced by vascular lumen. Tumor-derived circu-
lating VEGF-induced vascular dilation also exists in several
other tissues and organs including liver, adrenal gland, thyroid,
and pancreas (Cao et al., 2004; Eriksson et al., 2003; Feng et al.,
1999; Roberts and Palade, 1995; Yang et al., 2013b). Blood vas-
culatures in these organs are particularly sensitive to VEGF
stimulation, and VEGF is crucial for maintenance of microvessel
density (Kamba et al., 2006; Yang et al., 2013b). Hematopoietic
organs including BM, liver, and spleen contain sinusoidal capil-
laries (Kopp et al., 2009) that possess fenestrated endothelium
and incomplete basement membrane, which permit RBCs,
WBCs, as well protein molecules to pass through. Further dila-
tion of the sinusoidal capillaries in BM by VEGF would facilitate
intravasation of BMCs into the circulation. In fact, VEGF-
induced dilation of sinusoidal BM vessels is highly permeable
to large-molecular-weight dextran. Thus, at least two mecha-
nisms are potentially involved in circulating VEGF-induced
BMC depletion: (1) dilation of sinusoidal microvessels and in-
crease of vascular permeability in BM and (2) diminishing he-
matopoietic niches in BM.
Using both pharmacological and genetic approaches, we
have found that tumor-derived VEGF-induced BMCmobilization
can be completely blocked by inactivation of VEGFR2, but not
VEGFR1. These findings are surprising because VEGFR2 is not
prominently expressed in BMCs and our localization study
shows VEGFR2 expression is restricted in endothelial cells in
BM. Notably, genetic deletion of VEGFR2 in endothelial cells
largely impaired circulating VEGF-induced mobilization, indi-
cating that the endothelial VEGFR2 mediates BMC mobilization.
Although Tie2 expression is not restricted in endothelial cells,
specific expression of VEGFR2 in BM endothelial cells would
restrict the Tie2CreERT recombinase activity to endothelial cells.
Thus, the Vegfr2lox/loxTie2CreERT system in our experimental
model system is rather restricted to endothelial cells in BM. To
the best of our knowledge, this unexpected mechanism has
not been described for VEGF-induced mobilization of BMCs.
Thus, our findings provide mechanistic insights on how BMCs
are mobilized by VEGF under many pathological conditions. In
addition to VEGF and VEGFR2 inhibitors, it is likely other angio-
genesis inhibitors such as NADPH oxidase inhibitors (Bartus
et al., 2011; Bhandarkar et al., 2009; Garufi et al., 2014; MunsonCet al., 2012) could also alleviate VEGF-induced anemia. Despite
our evidence-based claims, we cannot exclude other possible
mechanisms of VEGF-related BMC mobilization. For example,
VEGF has been shown to play an important role in mobilization
of circulating endothelial precursor cells without significantly
affecting BM vasculatures (Lyden et al., 2001). In MMP9-defi-
cient mice, mobilization of VEGF is impaired, leading to defective
mobilization of CD45+ myeloid cells (Du et al., 2008). It is likely
that VEGFR1 plays a role in that experimental system. Thus,
VEGF-induced BMC cell mobilization may involve complex
mechanisms by which different BM cell populations are mobi-
lized by distinct pathways.
Cancer patients, especially those with advanced disease,
often suffer from systemic diseases including cancer cachexia
and paraneoplastic syndrome. Anemia is one of the most com-
mon systemic disorders seen in patients with various types of
cancers. Our present findings in mouse tumor models demon-
strated that tumor-derived circulating VEGF significantly contrib-
utes to tumor-associated hematopoiesis suppression in BM. In
fact, these findings are pathophysiologically and clinically rele-
vant. It is known that human tumors often express VEGF at
high levels as compared with their healthy tissue counterparts
(Jubb et al., 2004). In particular, a subset of human RCC tumor
tissues expresses VEGF to an extremely high level due to car-
rying mutations in the VHL gene (Jubb et al., 2004). Functional
impairment of VHL leads to stabilization of HIF-1a that transcrip-
tionally upregulates VEGF expression (Maxwell et al., 1999). It is
known that a substantial number of human RCC patients suffer
from paraneoplastic anemia, exhibiting sinusoidal dilation of
vasculatures in multiple tissues and organs (Cao, 2010). For
example, an early randomized autopsy study of 45 RCC patients
showed that 20%of RCCpatients exhibited sinusoidal dilation of
liver microvessels (Aoyagi et al., 1989). It is likely that their BM
microvessels might also become dilated. In our present study,
we show that human tumor cells carrying VHLmutations express
high levels of VEGF, which causes sinusoidal dilation of BM
microvessels. Interestingly, replacement of the mutated VHL
with the WTVHL in the same RCC cells completely abrogates
VEGF-induced vascular phenotypes in BM, indicating that func-
tionally defective VHL mutations are responsible for high-VEGF
expression and vascular phenotypes in other nonmalignant tis-
sues. This finding also implies that functionally defective VHL
mutations could potentially predict BM anemia in RCC patients
and even anti-VEGF drug responses. In fact, RCC patients
remain one of the particular cancer populations that benefit the
most from anti-VEGF therapy (Brugarolas, 2007). Thus, our find-
ings are clinically relevant.
VEGF-induced sinusoidal dilation is the mechanism for BM
hematopoiesis suppression, and therapeutic interference of
the systemic effect would be beneficial for host survival. Given
the known fact that tumor tissues contain high numbers of in-
flammatory cells and other hematopoietic cells that collectively
contribute to an invasive phenotype and antiangiogenic drug
resistance, our present findings imply that blocking the sys-
temic effect of tumor-derived VEGF would be an important
approach for antiangiogenic cancer therapy. In support of
this view, in preclinical tumor models, survival improvement
has been associated with off-tumor targets of anti-VEGFell Reports 9, 569–580, October 23, 2014 ª2014 The Authors 577
drugs. Our findings also indicate that normal structures and
architectures of BM microvessels are crucial for sustaining
physiological hematopoiesis, and interference of BM capillary
structures would lead to severe functional impairment. Taken
together, our data uncover yet another complex mechanism
by which tumor-derived VEGF manipulates the host tissues
for the benefit of tumor growth, invasion, and escaping drug
resistance.
EXPERIMENTAL PROCEDURES
Animals
WTC57Bl6 and EGFP transgenic mice at ages of 6–8 weeks old were obtained
from the Department of Microbiology, Tumor and Cell Biology, Karolinska
Institute. Vegfr1TK/ homozygous mice were obtained from Dr. Shibuya
Masabumi (University of Tokyo), Vegfrlox/lox mice were obtained from
Dr. Guo-Hua Fong (University of Connecticut Health Center) generated by
Dr. Sato Thomas (Nara Institute of Science and Technology), and Tie2creERT
mice were obtained from the European Mouse Mutant Archive Organization
generated by Dr. Arnold Bernd. Mice are all bred at the Karolinska Institute.
All animal studies were reviewed and approved by the North Stockholm Exper-
imental Animal Ethical Committee.
Cell Culture and Reagents
Murine fibrosarcoma cells (T241) were cultured in Dulbecco’smodified Eagle’s
medium (HyClone) supplemented with 10% fetal bovine serum (HyClone). A
rabbit anti-mouse VEGF-neutralizing antibody (BD0801) was obtained from
Simcere Pharmaceutical R&D (Yang et al., 2013a, 2013b). An anti-mouse
VEGFR1-neutralizing antibody and a rat anti-mouse VEGFR2-neutralizing anti-
body were obtained from Dr. Zhenping Zhu at ImClone. A rat anti-mouse en-
domucin antibody was purchased from eBioscience (cat. no. 14-5851-85).
Mouse Tumor Models
Approximately 13106T241 tumorcells in100ml PBSweresubcutaneously inoc-
ulated on the dorsal back ofC57Bl6,Vegfr1TK/, orVegfr2lox/loxTie2CreERTmice.
Both 768-O RCC-WTVHL and 768-O RCC-mutVHL tumor cells in 100 ml PBS
were subcutaneously inoculated in immunodeficient mice. Anti-VEGFR1 and
anti-VEGFR2 antibodies were administrated intraperitoneally (i.p.) at a dose
of 200 mg/mouse twice a week. The anti-VEGF-neutralizing antibody was i.p.
injected at a dose of 100 mg/mouse. Treatment with antibodies started when
tumor volume were approximately 0.3 cm3, and treatment lasted for 2 weeks.
Bone Marrow Transplantation
Femur and tibia bones were dissected from the donor EGFPmice immediately
after cervical dislocation. BMCswere flushed out with RPMImedium using 21-
gauge needles and filtered through a 70 mm nylon mesh cell strainer. BMCs
were collected in a 50 ml falcon tube, centrifuged at 1,500 rpm for 6 min,
and resuspended in cold PBS. Recipient mice were irradiated at 900 rad
gamma rays. Approximately 1.5 3 106 donor BMCs were injected into the
lateral tail vein of each recipient mouse.
Immunohistochemistry
Fresh bone samples were fixed in 4% paraformaldehyde at 4C overnight and
washed with PBS before paraffin embedding. The embedded samples were
cut (5 mm in thickness) and baked at 60C overnight. Antigen retrieval was
achieved using an unmasking solution (Vector Labs; H3300). Samples were
blocked with a blocking buffer (4% goat serum in PBS) at room temperature
(RT) for 30min. A rat anti-mouse endomucin antibody (eBioscience; 1:200 dilu-
tion in blocking buffer) was used for incubation at 4C overnight. A secondary
fluorescent-conjugated antibody (goat anti-rat Alexa Fluor 555; Invitrogen;
A21434; 1:400 dilution in blocking buffer) was incubated at RT for 1 hr. A rabbit
anti-mouse VEGFR2 (T104) antibody (1:100 dilution in blocking buffer) or a rat
anti-mouse Tie2 antibody (eBioscience E04662; 1:100 dilution in blocking
buffer) were used for incubation at 4C overnight. Secondary fluorescent-con-
jugated antibodies (goat anti-rat Alexa Fluor 555; Invitrogen; A21434; 1:400578 Cell Reports 9, 569–580, October 23, 2014 ª2014 The Authorsdilution in blocking buffer) and goat anti-rabbit (Alexa 488; Invitrogen; 1:400
dilution in blocking buffer) were incubated at RT for 1 hr. Slides were mounted
with Vectashield (Vector Labs; H-1200). Paraffin-embedded samples were
sectioned at a thickness of 5 mm and stained with hematoxylin-eosin as
described (Hosaka et al., 2013; Lim et al., 2012; Xue et al., 2010, 2012).Immunoblotting
Equal amounts of cell lysates were subjected to western blot analysis to detect
phosphorylated VEGFR2 by incubation with antibodies against phospho-
VEGFR2 (2471; Cell Signaling Technology) was followed by secondary anti-
body incubation. For analysis of VEGFR1 activation, BMCs were collected
from WT and Vegfr1TK/ and stimulated with recombinant VEGF for 15 min
prior to lysis. Total lysates were incubated with an anti-VEGFR1 antibody
(ImClone) followed by protein A/G Agarose (Santa Cruz Biotechnology; sc-
2003) immunoprecipitation. Samples were subjected to western blot analysis
with antibodies against total phosphotyrosine (4G10; 05-1050; Millipore) fol-
lowed by secondary antibodies. b-actin (3700S; Cell Signaling Technology)
was used as loading control for all blots. Positive signals were visualized using
an Odyssey CLx system (LI-COR).ELISA
Mouse and human VEGF were detected using commercially available VEGF
ELISA kits (R&D Systems). All procedures were performed according to the
manufacturer’s instructions.Statistical Analysis
For quantification analysis, data were analyzed using two-tailed Student’s
t test. *p < 0.05; **p < 0.01; ***p < 0.001.SUPPLEMENTAL INFORMATION
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